查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1631230

导管相关泌尿道感染治疗的全球市场 - 全球产业分析，规模，占有率，成长，趋势，预测(2032年)

Catheter Associated Urinary Tract Infections Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032
出版日期: | 出版商: Fairfield Market Research | 英文 216 Pages | 商品交期: 2-5个工作天内

价格
简介目录

受治疗方法的进步、创新的药物方案以及感染预防意识的不断提高的推动，全球导管相关尿道感染 (CAUTI) 治疗市场预计将出现显着增长。 CAUTI 是医疗保健环境中的常见併发症，需要有针对性的治疗介入来管理和预防与导尿管使用相关的细菌感染。

市场洞察

预计到 2025 年，CAUTI 治疗市场规模将达到 15 亿美元，到 2032 年将进一步扩大至 19.3 亿美元，复合年增长率为 3.60%。由于医疗机构广泛使用导尿管以及对抗生素抗药性的担忧日益增加，导致 CAUTI 盛行率不断上升，影响了市场的成长轨迹。由于治疗技术的进步和对感染预防的日益重视，全球导管相关泌尿道感染治疗市场具有巨大的成长潜力。透过对研发和协作努力的策略性投资，领先的公司能够很好地应对 CAUTI 管理不断变化的课题，确保改善患者的治疗效果并持续扩大市场。此外，家庭医疗保健和远距医疗的兴起凸显了可访问和创新的治疗解决方案的重要性，为未来几年的变革性医疗保健分析铺平了道路。

全球人口老化将增加对导尿管和有效感染控制的需求，从而推动市场成长。创新抗生素、防腐剂和抗感染导管材料的开发克服了传统治疗的课题并改善了患者的治疗效果。传统抗生素抗药性的增强为新的治疗方法创造了机会，例如抗菌涂层和替代药物配方。

本报告提供全球导管相关泌尿道感染治疗市场相关调查，提供市场概要，以及各药物类型，各适应症类型，各流通管道，及各地区趋势，及市场参与市场企业的竞争趋势等资讯。

目录

第1章 摘要整理

第2章 市场概要

  • 市场定义和市场区隔
  • 市场动态
  • 价值链分析
  • 波特的五力分析
  • COVID-19影响分析
  • 乌克兰·俄罗斯纠纷的影响
  • 经济概要
  • 大环境分析

第3章 全球导管相关泌尿道感染治疗市场预测，2019年～2032年

  • 全球导管相关泌尿道感染治疗市场预测，各药物类型，金额(10亿美元)，2019年～2032年
  • 全球导管相关泌尿道感染治疗市场预测，各适应症类型，金额(10亿美元)，2019年～2032年
  • 全球导管相关泌尿道感染治疗市场预测，各流通管道，金额(10亿美元)，2019年～2032年
  • 全球导管相关泌尿道感染治疗市场预测，各地区，金额(10亿美元)，2019年～2032年

第4章 北美的导管相关泌尿道感染治疗市场预测，2019年～2032年

第5章 欧洲的导管相关泌尿道感染治疗市场预测，2019年～2032年

第6章 亚太地区的导管相关泌尿道感染治疗市场预测，2019年～2032年

第7章 南美的导管相关泌尿道感染治疗市场预测，2019年～2032年

第8章 中东·非洲的导管相关泌尿道感染治疗市场预测，2019年～2032年

第9章 竞争情形

  • 各流通管道和各适应症类型的热图
  • 各製造厂商和各适应症类型的热图
  • 企业市场占有率分析，2024年
  • 竞争仪表板
  • 企业简介
    • Pfizer Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline (GSK)
    • AstraZeneca
    • Bayer AG
    • Johnson & Johnson
    • Novartis International AG
    • Sanofi
    • Roche Holding AG
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company
    • Abbott Laboratories
    • Astellas Pharma Inc.
    • Boehringer Ingelheim
    • Daiichi Sankyo Company, Limited
    • Gilead Sciences, Inc.

第10章 附录

简介目录

The global catheter-associated urinary tract infections (CAUTIs) treatment market is poised for significant growth, driven by advancements in treatment modalities, innovative drug formulations, and increasing awareness of infection prevention. CAUTIs, a prevalent complication in healthcare settings, necessitate targeted therapeutic interventions to manage and prevent bacterial infections associated with urinary catheter use.

Market Insights

The CAUTIs treatment market is expected to reach a value of $1.50 billion by 2025 and expand further to $1.93 billion by 2032, registering a compound annual growth rate (CAGR) of 3.60%. The market's growth trajectory is influenced by the increasing prevalence of CAUTIs, driven by the widespread use of urinary catheters in healthcare facilities, and the rising concern of antibiotic resistance. The global catheter-associated urinary tract infections treatment market offers significant growth potential, driven by advancements in therapeutic technologies and a growing focus on infection prevention. With strategic investments in R&D and collaborative efforts, key players are poised to address the evolving challenges of CAUTI management, ensuring improved patient outcomes and sustained market expansion. Furthermore, the rise of home healthcare and telemedicine underscores the importance of accessible and innovative treatment solutions, paving the way for a transformative healthcare Analysis in the years ahead.

Key Market Drivers

  • 1. Expanding Aging Population: The aging global population increases the demand for urinary catheters and effective infection management, boosting market growth.
  • 2. Advancements in Treatment Modalities: The development of innovative antibiotics, antiseptics, and infection-resistant catheter materials addresses the challenges of traditional therapies and improves patient outcomes.
  • 3. Antibiotic Resistance: The rising resistance to conventional antibiotics creates opportunities for novel therapeutic approaches, including antimicrobial coatings and alternative drug formulations.

Business Opportunities

  • 1. Rise in Home Healthcare and Telemedicine: The growing trend of home healthcare and remote medical services calls for patient-friendly and self-administered treatment options for CAUTIs. These approaches address the unique needs of patients outside traditional healthcare settings, providing significant market potential.
  • 2. Antimicrobial Coatings for Catheters: Technological advancements in catheters with controlled-release antimicrobial coatings present lucrative revenue opportunities, addressing both prevention and treatment needs. The integration of antimicrobial technologies in catheter design minimizes bacterial colonization risks, enhancing patient safety.
  • 3. Collaborative Research: Partnerships between pharmaceutical companies, healthcare providers, and research institutions drive innovation in CAUTI treatments, enhancing market dynamics. These collaborations foster the development of advanced therapeutic solutions tailored to emerging healthcare challenges.

Regional Analysis

  • Europe: Dominates the market due to advanced healthcare infrastructure, robust research initiatives, and strategic collaborations that drive innovation. Regulatory support and funding for infection control further bolster Europe's market leadership.
  • South Asia & Pacific: Emerges as the fastest-growing region, fueled by population expansion, increasing awareness, and evolving healthcare infrastructure. The adoption of modern healthcare practices and government-backed programs support market growth in this region.
  • North America: Maintains a strong market presence owing to well-established healthcare systems and significant investment in medical research. The region's focus on technological integration enhances CAUTI treatment strategies.

Key Players

Prominent companies shaping the CAUTIs treatment market include:

  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline (GSK)
  • AstraZeneca
  • Bayer AG
  • Johnson & Johnson
  • Novartis International AG
  • Sanofi
  • Roche Holding AG
  • Abbott Laboratories
  • Bristol-Myers Squibb Company
  • Astellas Pharma Inc.
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.

Market Segmentation

1. By Drug Type:

    Penicillin & Combinations Quinolones Cephalosporins Aminoglycoside Antibiotics Sulphonamides Azoles and Amphotericin B Tetracycline Nitrofurantoin

2. By Indication Type:

    Asymptomatic CAUTI (Bacteriuria) Symptomatic CAUTI (Bacteremic)

3. By Distribution Channel:

    Hospital Pharmacies Gynecology and Urology Clinics Drug Stores Retail Pharmacies Online Drug Stores

4. By Region:

    North America Europe Asia Pacific Latin America Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Catheter Associated Urinary Tract Infections Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2024
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

  • 3.1. Global Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
    • 3.1.1. Key Highlights
      • 3.1.1.1. Penicillin & Combinations
      • 3.1.1.2. Quinolones
      • 3.1.1.3. Caphalosporin
      • 3.1.1.4. Aminoglycoside Antibiotics
      • 3.1.1.5. Sulphonamides
      • 3.1.1.6. Azoles and Amphotericin B
      • 3.1.1.7. Tetracycline
      • 3.1.1.8. Nitrofura
  • 3.2. Global Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
    • 3.2.1. Key Highlights
      • 3.2.1.1. Asymptomatic CAUTI (Bacteriuria)
      • 3.2.1.2. Symptomatic CAUTI (Bacteremic)
  • 3.3. Global Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospital Pharmacies
      • 3.3.1.2. Gynaecology and Urology Clinics
      • 3.3.1.3. Drug Stores
      • 3.3.1.4. Retail Pharmacies
      • 3.3.1.5. Online Drug Stores
  • 3.4. Global Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Region, Value (US$ Bn), 2019 - 2032
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

  • 4.1. North America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
    • 4.1.1. Key Highlights
      • 4.1.1.1. Penicillin & Combinations
      • 4.1.1.2. Quinolones
      • 4.1.1.3. Cephalosporin
      • 4.1.1.4. Aminoglycoside Antibiotics
      • 4.1.1.5. Sulphonamides
      • 4.1.1.6. Azoles and Amphotericin B
      • 4.1.1.7. Tetracycline
      • 4.1.1.8. Nitrofura
  • 4.2. North America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
    • 4.2.1. Key Highlights
      • 4.2.1.1. Asymptomatic CAUTI (Bacteriuria)
      • 4.2.1.2. Symptomatic CAUTI (Bacteremic)
  • 4.3. North America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospital Pharmacies
      • 4.3.1.2. Gynaecology and Urology Clinics
      • 4.3.1.3. Drug Stores
      • 4.3.1.4. Retail Pharmacies
      • 4.3.1.5. Online Drug Stores
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 4.4.1.2. U.S. Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 4.4.1.3. U.S. Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 4.4.1.4. Canada Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 4.4.1.5. Canada Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 4.4.1.6. Canada Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

  • 5.1. Europe Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Penicillin & Combinations
      • 5.1.1.2. Quinolones
      • 5.1.1.3. Cephalosporin
      • 5.1.1.4. Aminoglycoside Antibiotics
      • 5.1.1.5. Sulphonamides
      • 5.1.1.6. Azoles and Amphotericin B
      • 5.1.1.7. Tetracycline
      • 5.1.1.8. Nitrofura
  • 5.2. Europe Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Asymptomatic CAUTI (Bacteriuria)
      • 5.2.1.2. Symptomatic CAUTI (Bacteremic)
  • 5.3. Europe Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospital Pharmacies
      • 5.3.1.2. Gynaecology and Urology Clinics
      • 5.3.1.3. Drug Stores
      • 5.3.1.4. Retail Pharmacies
      • 5.3.1.5. Online Drug Stores
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.2. Germany Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.3. Germany Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.4.1.4. U.K. Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.5. U.K. Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.6. U.K. Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.4.1.7. France Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.8. France Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.9. France Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.4.1.10. Italy Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.11. Italy Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.12. Italy Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.4.1.13. Turkey Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.14. Turkey Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.15. Turkey Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.4.1.16. Russia Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.17. Russia Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.18. Russia Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.4.1.19. Rest of Europe Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.20. Rest of Europe Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 5.4.1.21. Rest of Europe Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

  • 6.1. Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Penicillin & Combinations
      • 6.1.1.2. Quinolones
      • 6.1.1.3. Cephalosporin
      • 6.1.1.4. Aminoglycoside Antibiotics
      • 6.1.1.5. Sulphonamides
      • 6.1.1.6. Azoles and Amphotericin B
      • 6.1.1.7. Tetracycline
      • 6.1.1.8. Nitrofura
  • 6.2. Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Asymptomatic CAUTI (Bacteriuria)
      • 6.2.1.2. Symptomatic CAUTI (Bacteremic)
  • 6.3. Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospital Pharmacies
      • 6.3.1.2. Gynaecology and Urology Clinics
      • 6.3.1.3. Drug Stores
      • 6.3.1.4. Retail Pharmacies
      • 6.3.1.5. Online Drug Stores
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.2. China Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.3. China Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.4.1.4. Japan Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.5. Japan Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.6. Japan Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.4.1.7. South Korea Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.8. South Korea Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.9. South Korea Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.4.1.10. India Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.11. India Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.12. India Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.4.1.13. Southeast Asia Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.14. Southeast Asia Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.15. Southeast Asia Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.4.1.16. Rest of Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.17. Rest of Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 6.4.1.18. Rest of Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

  • 7.1. Latin America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Penicillin & Combinations
      • 7.1.1.2. Quinolones
      • 7.1.1.3. Cephalosporin
      • 7.1.1.4. Aminoglycoside Antibiotics
      • 7.1.1.5. Sulphonamides
      • 7.1.1.6. Azoles and Amphotericin B
      • 7.1.1.7. Tetracycline
      • 7.1.1.8. Nitrofura
  • 7.2. Latin America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
      • 7.2.1.1. Asymptomatic CAUTI (Bacteriuria)
      • 7.2.1.2. Symptomatic CAUTI (Bacteremic)
  • 7.3. Latin America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospital Pharmacies
      • 7.3.1.2. Gynaecology and Urology Clinics
      • 7.3.1.3. Drug Stores
      • 7.3.1.4. Retail Pharmacies
      • 7.3.1.5. Online Drug Stores
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 7.4.1.2. Brazil Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 7.4.1.3. Brazil Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.4.1.4. Mexico Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 7.4.1.5. Mexico Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 7.4.1.6. Mexico Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.4.1.7. Argentina Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 7.4.1.8. Argentina Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 7.4.1.9. Argentina Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.4.1.10. Rest of Latin America Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 7.4.1.11. Rest of Latin America Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 7.4.1.12. Rest of Latin America Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

  • 8.1. Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Penicillin & Combinations
      • 8.1.1.2. Quinolones
      • 8.1.1.3. Cephalosporin
      • 8.1.1.4. Aminoglycoside Antibiotics
      • 8.1.1.5. Sulphonamides
      • 8.1.1.6. Azoles and Amphotericin B
      • 8.1.1.7. Tetracycline
      • 8.1.1.8. Nitrofura
  • 8.2. Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
    • 8.2.1. Key Highlights
      • 8.2.1.1. Asymptomatic CAUTI (Bacteriuria)
      • 8.2.1.2. Symptomatic CAUTI (Bacteremic)
  • 8.3. Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospital Pharmacies
      • 8.3.1.2. Gynaecology and Urology Clinics
      • 8.3.1.3. Drug Stores
      • 8.3.1.4. Retail Pharmacies
      • 8.3.1.5. Online Drug Stores
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.2. GCC Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.3. GCC Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.4.1.4. South Africa Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.5. South Africa Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.6. South Africa Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.4.1.7. Egypt Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.8. Egypt Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.9. Egypt Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.4.1.10. Nigeria Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.11. Nigeria Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.12. Nigeria Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.4.1.13. Rest of Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.14. Rest of Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
      • 8.4.1.15. Rest of Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Distribution Channel vs by Indication Type Heat map
  • 9.2. Manufacturer vs by Indication Type Heatmap
  • 9.3. Company Market Share Analysis, 2024
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Pfizer Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Merck & Co., Inc.
    • 9.5.3. GlaxoSmithKline (GSK)
    • 9.5.4. AstraZeneca
    • 9.5.5. Bayer AG
    • 9.5.6. Johnson & Johnson
    • 9.5.7. Novartis International AG
    • 9.5.8. Sanofi
    • 9.5.9. Roche Holding AG
    • 9.5.10. Eli Lilly and Company
    • 9.5.11. Bristol-Myers Squibb Company
    • 9.5.12. Abbott Laboratories
    • 9.5.13. Astellas Pharma Inc.
    • 9.5.14. Boehringer Ingelheim
    • 9.5.15. Daiichi Sankyo Company, Limited
    • 9.5.16. Gilead Sciences, Inc.

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations